JMP Securities analyst Constantine Davides has maintained their bullish stance on USPH stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Constantine Davides has given his Buy rating due to a combination of factors including U.S. Physical Therapy’s strong financial performance and strategic growth initiatives. The company reported impressive fourth-quarter results with revenue and adjusted EBITDA surpassing both estimates and consensus, indicating robust operational efficiency. The acquisition of Metro has also contributed significantly to revenue, and the company ended the year with more clinics than anticipated, showcasing successful expansion efforts.
Additionally, the Industrial Injury Prevention services segment demonstrated substantial growth, and the company’s balance sheet remains healthy with a manageable debt level. Looking ahead, the 2025 outlook is promising with expected double-digit revenue growth in key areas and a favorable EBITDA guidance. The company’s valuation appears attractive, trading below its historical average, and the potential for accretive acquisitions further supports the positive rating. These factors combined present a compelling case for the Buy recommendation.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $112.00 price target.